Skip to content

    Cipla Limited

    India's 3rd-largest drugmaker; sells generics, inhalers and consumer health across 74 markets

    Healthcare
    Healthcare
    View CIPLA earnings calls
    ₹1,351.8
    +1.23% from avg

    Overview

    Price

    ₹1,351.8

    Market Cap

    ₹1.1L Cr

    Sector

    Healthcare

    Healthcare

    Rank

    3

    Performance

    Explore CIPLA

    Promise TrackerConcall Analysis

    Financials

    Income Statement

    Financial Trajectories

    11
    Quarterly

    Balance Sheet

    Balance Sheet

    ₹ Cr · Annual
    Line itemFY20FY21FY22FY23FY24FY25FY26FY26
    LiabilitiesEquity Capital161161161161161162162162
    Reserves17.2k19.8k22.4k24.5k27.8k31.9k32.8k34.0k
    Borrowings652235046117467125
    Other Liabilities3.0k3.0k2.9k2.9k3.0k3.3k6.8k4.2k
    Total Liabilities20.4k23.0k25.4k27.6k31.1k35.6k40.2k38.5k
    AssetsFixed Assets4.2k4.1k3.9k3.8k3.7k3.9k10.9k5.2k
    CWIP3203552685046706381.4k978
    Investments7.2k9.7k11.0k11.9k13.8k17.4k8.2k17.6k
    Other Assets8.7k8.8k10.3k11.4k12.9k13.7k19.6k14.7k
    Total Assets20.4k23.0k25.4k27.6k31.1k35.6k40.2k38.5k

    Valuation

    Assumptions

    Current — CIPLA
    Price
    ₹1,352
    EPS (TTM)
    ₹38.06
    PE (TTM)
    35.5
    Profit growth
    9.7%
    ₹

    The Earnings Per Share over the last 12 months.

    %

    Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).

    Pre-filled with the lower of median (28.2×) and current (35.5×) PE — the conservative anchor.

    %

    The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.

    Valuation

    Current price
    ₹1,352
    vs
    Fair value · 15% return
    ₹728
    46%Overvalued

    At 9.7% growth and a 28× exit, ₹1352 only delivers your return if you pay ₹728. The price is currently baking in 23% growth.

    EPS grows 9.7%/yr for 5 years, then fades to 6% over 2, exits at 28×.

    YearGrowthEPS (₹)
    FY279.7%41.75
    FY289.7%45.80
    FY299.7%50.24
    FY309.7%55.12
    FY319.7%60.46
    FY327.8% ·fade65.21
    FY336.0% ·fade69.12

    Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.

    Learn to analyse Cipla Limited

    Guides on how to read this kind of business and the numbers that matter.